CBP/p300 bromodomain inhibitor AUR-107

{
  "id": "MLC-T-ONC-012347",
  "term": "CBP/p300 bromodomain inhibitor AUR-107",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the bromodomain of the histone acetyltransferase (HAT) paralogs, CREB binding protein (CBP; CREBBP) and p300 (E1A-associated protein p300; p300 HAT), with potential immunomodulating and antineoplastic activities. Upon oral administration, CBP/p300 bromodomain inhibitor AUR-107 targets and binds to the bromodomains of CBP and p300. This disrupts the acetylation of histones and other proteins and decreases regulatory T cells (Tregs) generation, inhibits its suppressive function and causes Tregs apoptosis. This modulates T-helper cells, induces an anti-tumor immune response and decreases tumor growth. The HAT paralogs CBP and p300 are key transcriptional co-activators that are essential for a multitude of cellular processes and play a key role in the regulation of gene expression in both tumor and immune cells.",
  "synonyms": [
    "CBP/p300 inhibitor AUR-107",
    "p300/CBP bromodomain inhibitor AUR107"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cbp-p300-bromodomain-inhibitor-aur-107/"
}